Now that your team has implemented the EHR, you will test whether it performs the desired functions and meet the requirements. Three (3) most common types of IT system testing are: Unit Testing or Component Testing implies that the individual components (clinical, administrative, pharmacy, lab., digital imaging, etc.) of the EHR system function as desired and specified in the RFP; Integrated Testing means that these components function in harmony and interoperate; and Performance Testing (also called stress testing or maximum load testing) ensures that the system performs normally under maximum or significant load (happens in the morning when all staff starts working with EHR) to check for robustness, availability and error handling beyond the normal operational capacity. You were advised by your manager to schedule these tests. Thus, your team will undertake the above three types of testing before Closing or Signing off the project. He asked you to describe the methodology and steps you would perform to accomplish this task. You were asked to consult the following resources before proceeding: Electronic Health Record (EHR) System Testing Plan https://www.healthit.gov/sites/default/files/playbook/pdf/ehr-system-testing-plan.pdf What is difference between Unit Testing and Integration Testing?
Medical management has always been the first therapeutic option to be tried and if the results fail, one can resort to surgical interventions. Medical treatment of menorrhagia should aim to relieve symptoms, improve quality of life and to avoid the risk of surgery. The present study was conducted to evaluate the efficacy and safety of oral ormeloxifene and levonorgesterol IUCD in the management of dysfunctional uterine bleeding. Our study included patients with menorrhagia in the age group 31-50years attending the outpatient department or admitted as inpatients in the department of obstetrics and gynecology at Sri Siddhartha Medical College and Research Centre, Tumkur. Patients were divided into 2 groups of ormeloxifene and levonorgesterol IUCD. Patients were followed up for 6 months. Pre and post treatment outcome measures in both groups studied were as follows. – Pre treatment and post treatment assessment of menstrual blood loss objectively by pictorial blood loss assessment chart. – Blood hemoglobin levels – Endometrial thickness ( transvaginal scan). Among 80 patients included in the study, two groups contained 40 patients each. Out of 40 who were treated with oral ormeloxifene, 30 patients attained amenorrhea, 2 patients underwent hysterectomy, 8 patients symptomatically improved. Out of 40 patients treated with levonorgesterol IUCD , 32 patients attained amenorrhea, 1 patient underwent hysterectomy, 4 patients symptomatically improved and 3 patients lost to follow up. Amenorrhea in our study was defined as absence of bleeding for 3 consecutive cycles. Symptomatically improved patients = patients in whom cycles were 45-60 days but there was significant reduction in bleeding, reduction in PBAC score, reduction in endometrial thickness and increase in hemoglobin percentage. In this study, the patients who are treated with oral ormeloxifene shows there was significant reduction in menstrual blood loss as assessed by fall in PBAC score (Table2). The mean pretreatment menstrual blood loss (PBAC score) was 174.20±56.93 which reduced to 22.87±29.90 at 3 months and 3.74±10.99 at 6 months with treatment. There was significant reduction in menstrual blood loss in patients with ormeloxifene. The results of this study (table-2) suggests that the rise in haemoglobin level at the end of 6 months of treatment was 11.03±1.02 compared to the pretreatment level of 10.22±1.36. The rise in haemoglobin level at the end of 6 months was significant. The mean endometrial thickness (Table-2) in the pretreatment group was 9.32±3.10 and there was decrease >GET ANSWER